CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹61 Cr | ₹-31 Cr | ₹82 Cr | ₹184 Cr | ₹622 Cr |
What is the latest Total Non-Current Liabilities ratio of CIPLA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹61 Cr |
| Mar2025 | ₹-31 Cr |
| Mar2024 | ₹82 Cr |
| Mar2023 | ₹184 Cr |
| Mar2022 | ₹622 Cr |
How is Total Non-Current Liabilities of CIPLA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹61 Cr | Positive | |
| Mar2025 | ₹-31 Cr | Negative | |
| Mar2024 | ₹82 Cr | -55.36 | |
| Mar2023 | ₹184 Cr | -70.48 | |
| Mar2022 | ₹622 Cr | - | |
Compare Total Non-Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹111,490.2 Cr | 2% | -0.2% | -14.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,662.0 Cr | 2% | -4.4% | 3.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹257,903.0 Cr | 7.1% | 2.5% | 46.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,306.0 Cr | 1.4% | -5.7% | 27.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,699.0 Cr | 3.6% | 8% | 4.2% | Stock Analytics | |
| MANKIND PHARMA | ₹102,797.0 Cr | 8.1% | -2.2% | 1.2% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 2% |
-0.2% |
-14.3% |
| SENSEX | 1.8% |
2.3% |
-11.9% |
You may also like the below Video Courses